Lexicon Pharmaceuticals, Inc. · NASDAQ:LXRX
Lexicon Pharmaceuticals — Investor Presentation (September 2024)
17 slides from Lexicon Pharmaceuticals's investor presentation, September 2024
Slide 1: Lexicon Corporate Presentation
Lexicon Corporate Presentation September 2024
Slide 2: Forward-Looking Statements
Forward-Looking Statements • This presentation, including any oral presentation accompanying it, contains “forward-looking statements,” including statements about Lexicon’s strategy and operating performance and events or developments that we expect or anticipate will occur in the future, such as pr
Slide 3: 2024 has been transformational for Lexicon
Company Overview 2024 has been transformational for Lexicon With significant near-term potential catalysts through 2025 Resubmitted NDA Phase 3 study Enrollment in LX9851, an oral Strategic for ZYNQUISTA™ underway of Phase 2b study of drug candidate for realignment of (sotagliflozin) for sotaglifloz
Slide 4: Lexicon Lead to Succeed strategy
Company Overview Lexicon Lead to Succeed strategy Designed to drive value for all stakeholders First or only in therapy or class LEAD TO SUCCEED STRATEGY Large Leading markets with medical & significant need commercial presence Driving value and growth for Lexicon with opportunities that have the mo
Slide 5: Lead to Succeed is designed to drive value and growth across portfolio
Company Overview Lead to Succeed is designed to drive value and growth across portfolio Refocusing resources where Lexicon has potential to lead and succeed Prioritizing investment in ZYNQUISTA™ ahead of potential launch Continued targeted promotion of INPEFA® in Heart Failure, focused on growth and
Slide 6: Sotagliflozin has three potential indications
Sotagliflozin Sotagliflozin has three potential indications which position it as a “pipeline in a pill” Sotagliflozin INPEFA ZYNQUISTA Sotagliflozin Heart Failure Type 1 Diabetes Hypertrophic Cardiomyopathy Approved PDUFA Dec. 20, 2024 Future Opportunity Two SGLT alternatives No SGLTs Indicated No S
Slide 7: Zynquista has potential to address a major treatment gap
Zynquista Zynquista has potential to address a major treatment gap with an opportunity to demonstrate benefit:risk at AdCom Oct 31 High unmet need for adjunctive glycemic control in adults 1 with T1D and CKD Estimated >400k addressable patients in US alone per 2 proposed label Potential to be only a
Slide 8: Glycemic control is critical in T1D + CKD
Zynquista Glycemic control is critical in T1D + CKD yet insulin alone often not sufficient Type 1 Diabetes Involves Significant Short- and Long-Term Complications Hypoglycemia1 Neuropathy2 Clinically Observed Benefits of ZYNQUISTA Nephropathy3 Retinopathy4 Glycemic control on top of optimized insuli
Slide 9: SONATA Phase 3 study has commenced
Sotagliflozin HCM SONATA Phase 3 study has commenced with pragmatic design designed to enable a broad indication for HCM Sotagliflozin 400 mg* (N = 250) R FDA Feedback Supports 1:1 Potential Broad Label in Placebo (N = 250) HCM Based on Single Phase 3 Study Up to 14 days 4-week 26-week Double-blind
Slide 10: Potential to address a substantial treatment gap in HCM
Sotagliflozin HCM Potential to address a substantial treatment gap in HCM positioned between, or on top of, use of basal therapies and CMIs Limitations Potential Advantages HCM of Current Care of Sotagliflozin • Access to care Potential for Fatigue broad adoption • Cost Ease in prescribing • Complex
Slide 11: LX9211 has potential to redefine standard of care for neuropathic pain
LX9211 LX9211 has potential to redefine standard of care for neuropathic pain with pipeline in a pill potential across NP and spasticity Proof of concept High unmet achieved – FDA fast track medical need designation Potential for significant Late-stage clinical commercial opportunity development und
Slide 12: PROGRESS Phase 2b study in DPNP is recruiting strongly
LX9211 PROGRESS Phase 2b study in DPNP is recruiting strongly with pragmatic design for "real world" implementation Patient Safety Follow- Treatment Period Population up 1. Aligns with real-world utilization of DPNP LX9211 10 mg treatment: Adult patients LX9211 20 mg • Patients allowed to with a dia
Slide 13: LX9211 has the potential for multiple therapeutic applications
LX9211 LX9211 has the potential for multiple therapeutic applications and is potentially the first and only innovation on top of SoC in NP LX9211 Neuropathic Pain ✓ First-in-class mechanism ✓ AAK1 specifically chosen (over NaV1.8) ✓ Non-opioid ✓ Use alone or on top of existing therapy ✓ Statisticall
Slide 14: LX9851 is the first and only investigational medicine to inhibit ACSL5
LX9851 LX9851 is the first and only investigational medicine to inhibit ACSL5 with mechanism that is complementary and independent to incretins Challenges Remain in Potential Advantages Biology-based Mechanism to with GLP-1 treatment of LX9851 Address Obesity • Muscle wasting Oral agent for chronic
Slide 15: Lexicon's pipeline is making significant progress
Company Overview Lexicon's pipeline is making significant progress and is positioned for near- and long-term company growth Preclinical Phase 1 Phase 2 Phase 3 Registration Approved INPEFA® (Sotagliflozin) Approved for Heart Failure ZYNQUISTA™ (Sotagliflozin) Type 1 Diabetes NDA resubmitted; Advisor
Slide 16: Lexicon has a significant number of near-term potential catalysts
Company Overview Lexicon has a significant number of near-term potential catalysts with potential to further drive the company transformation Pipeline Indication Planned Catalyst 2024 – 2025 ZYNQUISTA™ • PDUFA Goal Date Dec. 20, 2024; FDA • Type 1 Diabetes with Chronic Advisory Committee Meeting Oct
Slide 17: Thank You
Thank You w lexicon th Dharmaceuticals
Lexicon Pharmaceuticals — Investor Presentation (September 2024) on 6ix